MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 183 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NHHlSYdEgXSxdH;4bYMhSXO|YYm= MYGzJO69VQ>? M4DYcVczKGh? M4XoTGROW09? MVvJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NFPxU2UzODV5MUC2PS=>
A431 M2X0emtqdmG|ZTDBd5NigQ>? NV20OXJsPSEQvF2= Mn\rOUBp MVjEUXNQ MX\TeZBxemW|c3XzJJRp\SC|aXfuZYxqdmdib3[gRYt1KGGwZDDFdos> NH\BV5UzODV5MUC2PS=>
HepG2 NH[0O4dEgXSxdH;4bYMhSXO|YYm= M{nF[FExKM7:TR?= NWfFS|h4OjRiaB?= MlnWSG1UVw>? MVrT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NWfK[VhZOjF{MEW5NlU>
Sk-Hep1 M2\qbmN6fG:2b4jpZ{BCe3OjeR?= NF\uNo0yOCEQvF2= MoTxNlQhcA>? M3K0Z2ROW09? MljPV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni NWHUTVBTOjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;yN{DPxE1? M{nZPFUh\A>? MX\EUXNQ NFH1TJpKSzVyPUCuNVQh|ryP M331WlIyOjh7Mk[3
K1 cells harbored PIK3CA (E542K+/+) NWjTcmVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni0N{DPxE1? M{W2UlUh\A>? NWTHUWN1TE2VTx?= Mnm4TWM2OD1yLkWyJO69VQ>? M1n2d|IyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULBSXZsOyEQvF2= NFP1R2Y2KGR? NE[xV4ZFVVOR NWjnVnRYUUN3ME2wMlE5KM7:TR?= NUHTZ5V7OjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPXlY{KM7:TR?= NVPZbGt[PSCm Mn76SG1UVw>? NUOz[|lwUUN3ME2wMlI4KM7:TR?= Mn20NlEzQDl{Nke=
Hth7 cells harbored NRAS (Q61R+/−) NGXFfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12zS|Mh|ryP M3PwblUh\A>? M1XDNWROW09? NH7LUnZKSzVyPUSuOUDPxE1? MWGyNVI5QTJ4Nx?=
TPC1 cells harbored RET/PTC1 rearrangement NWmyU403T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XQb|Mh|ryP MXG1JIQ> NV3oNml4TE2VTx?= MYrJR|UxRTBwNUmg{txO NX\SUo5JOjF{OEmyOlc>
Hth74 M1;oZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7wbo4{KM7:TR?= NET5OIQ2KGR? NFXybpFFVVOR NUiwUpQ4UUN3ME2yMlE6KM7:TR?= MlPRNlEzQDl{Nke=
KAT18 M4Tadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWizJO69VQ>? MnHnOUBl MVrEUXNQ MXfJR|UxRTRwNkKg{txO MlHWNlEzQDl{Nke=
SW1736 NFLpSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iwNlExOCEQvF2= Mn;ZOUBl M3zEV2ROW09? M3zocmlEPTB;NEeuOVYh|ryP M{\QcFIyOjh7Mk[3
WRO NWfLN4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvENVAxOCEQvF2= NXLGVYZNPSCm MYPEUXNQ M2nB[GlEPTB-MUCwNEDPxE1? NXXZfGF7OjF{OEmyOlc>
TAD2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxNFAxKM7:TR?= MX21JIQ> M4XmWGROW09? MX\JR|UxRjFyMECg{txO MX:yNVI5QTJ4Nx?=
LN229 NVW2PHhXSXCxcITvd4l{KEG|c3H5 M2TYN|AvPSEQvF2= NIfYNJY3OCCq MUHEUXNQ MlvkRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? M2WydlIzODV5OUG0
T98G Ml7HRZBweHSxc3nzJGF{e2G7 NULvXJR[OC53IN88US=> MVO2NEBp M{fqfmROW09? NV7rbZc3SXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= NVLXWoxROjJyNUe5NVQ>
HC11 MUXGeY5kfGmxbjDBd5NigQ>? NHzO[lMyOCEQvF2= M362TFI1KGh? M2[y[mROW09? NUX3OHl2UW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>? M4W0dVIzPDJ4NkKx
MOLT-4 Mo[zR5l1d3SxeHnjJGF{e2G7 MUSxNEDPxE1? MmfLOFghcA>? NV;RUoZrTE2VTx?= NIjUc5JKSzVyPUGuO-KBkc7:TR?= NWGz[GV1OjJ4MUSyOFM>
CEM-R M2XxXWN6fG:2b4jpZ{BCe3OjeR?= M3;0blExKM7:TR?= NFrEO5Y1QCCq MXHEUXNQ MWjJR|UxRTNwM,MAje69VQ>? MonTNlI3OTR{NEO=
CEM-S M3;XdmN6fG:2b4jpZ{BCe3OjeR?= MmnpNVAh|ryP NHGxXog1QCCq MV7EUXNQ NFjJeXpKSzVyPUWuNgKBkc7:TR?= MlzwNlI3OTR{NEO=
MOLT-4 M2nUZ2Z2dmO2aX;uJGF{e2G7 NHLMOI4yOCEQvF2= NFXLNIkzPCCq NVWx[ldoTE2VTx?= NITlUYtDdG:la4OgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOnIH;mJJRp\SClZXzsJIN6[2yn NGfHXFczOjZzNEK0Ny=>
MOLT-4 MmHvSpVv[3Srb36gRZN{[Xl? NUC0TndHPOLCid88US=> NIjwXXY1KGh? MX\EUXNQ NWTo[GkyUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|NCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ MWeyNlYyPDJ2Mx?=
CEM-R NXPRXoF7TnWwY4Tpc44hSXO|YYm= M4rtOFTjiIoQvF2= MVK0JIg> M2LxcWROW09? M1\mW2lv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO0RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? Ml;YNlI3OTR{NEO=
CEM-S MX3GeY5kfGmxbjDBd5NigQ>? NH\IR5A16oDLzszN M4fXclQhcA>? NXjx[4trTE2VTx?= NXT4S2pVUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ M4\LS|IzPjF2MkSz
HepG2 cell MXrLbY5ie2ViQYPzZZk> M3LzTVIxKM7:TR?= MX6yOEBp NV7PcGtkTE2VTx?= MXjEc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV M2PCUVI{Pzl5M{G5
HepG2 cell M1rmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXwc5g{OCEQvF2= NUfUXGtpOjRiaB?= M17XU2ROW09? NELsc4NKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MmDvNlM4QTd|MUm=
HepG2 cell M{L6TWFxd3C2b4Ppd{BCe3OjeR?= Mmi3NlAh|ryP NH\5eWEzPCCq NX;GRWRITE2VTx?= M2SwXGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3zmR|I{Pzl5M{G5
GEO M3yyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3DOVAxKG6P NHXYe5o4OiCq NEnKcJdFVVOR NYDMNphqUW6qaXLpeJMh[2WubDDndo94fGh? M3;OWFI1PThzMkOx
CNE-1 NUDXS5ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TlU|ExKM7:TR?= MV:5OkBp MYLEUXNQ M1LKdGlEPTB;Mj65OkDPxE1? MYKyOVM{Pjl{NR?=
CNE-2 NWPPU29rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNEDPxE1? M1X3Slk3KGh? NH;r[|RFVVOR MXnJR|UxRTRwNUOg{txO Mm\BNlU{OzZ7MkW=
HONE-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LUVlExKM7:TR?= NFHM[pU6PiCq NHn5SlRFVVOR MoTUTWM2OD1|LkO3JO69VQ>? NVvhR45[OjV|M{[5NlU>
SUNE-1 NED0XHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom0NVAh|ryP MknBPVYhcA>? M1\uU2ROW09? NHv5UmZKSzVyPUCuOVIh|ryP MWCyOVM{Pjl{NR?=
CNE-2 NIrSXnZHfW6ldHnvckBCe3OjeR?= NWLPXGN1OTBizszN MXy0PEBp MkXnSG1UVw>? MnO2TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? NVn0VopMOjV|M{[5NlU>
HONE-1 M4LFcGZ2dmO2aX;uJGF{e2G7 NHLYNo8yOCEQvF2= NYnYeIJQPDhiaB?= NGW0[lJFVVOR M1zTXmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? M3zSSFI2OzN4OUK1
NEC8 M3LyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vYe2lEPTB;MD6wPVY2OSEQvF2= NUfVeWlmW0GQR1XS
P12-ICHIKAWA NV7ze49MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DzfGlEPTB;MD6xNVYzKM7:TR?= NF;teYFUSU6JRWK=
MDA-MB-175-VII M17UdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLETWM2OD1yLkGzO|M5KM7:TR?= NGDENItUSU6JRWK=
AsPC-1 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jqTGlEPTB;MD6yNlEzOiEQvF2= NUnPfmhzW0GQR1XS
T47D NIXY[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3PUI5KSzVyPUCuNlgzPSEQvF2= NIrWUVVUSU6JRWK=
HH NHz0bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz3fJdKSzVyPUCuN|AzQDNizszN Ml3jV2FPT0WU
MOLT-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HMSGlEPTB;MD6zNFMzKM7:TR?= MVrTRW5ITVJ?
ES5 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwM{S0OVUh|ryP Mk\6V2FPT0WU
RS4-11 M{DmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrITWM2OD1yLkO0OlEh|ryP MVnTRW5ITVJ?
KARPAS-45 NHrQdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPFTWM2OD1yLkO3N|IyKM7:TR?= NVXSUoNQW0GQR1XS
NCI-H720 NIfqO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX6TWM2OD1yLkO3Olc6KM7:TR?= Mo\TV2FPT0WU
H9 M1yzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETzVnlKSzVyPUCuN|g5QDNizszN M2\3S3NCVkeHUh?=
EFM-19 NY\F[5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwNESwNUDPxE1? NGPoclNUSU6JRWK=
SBC-1 M4iyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNESwN|Uh|ryP NIToclFUSU6JRWK=
A4-Fuk NYPDV3VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrpTWM2OD1yLkS2PFY5KM7:TR?= MW\TRW5ITVJ?
NCI-H1563 NEXWNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTZSJVRUUN3ME2wMlQ5OTh7IN88US=> MknMV2FPT0WU
HCC1419 M37ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LDVWlEPTB;MD60PFg6OiEQvF2= NEjQOHFUSU6JRWK=
H-EMC-SS MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzHTWM2OD1yLkS5PVM6KM7:TR?= MUPTRW5ITVJ?
BHT-101 NVLmbJNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n1VGlEPTB;MD61Nlk3OSEQvF2= NFr6eWNUSU6JRWK=
IGROV-1 NED6RnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwNUWyOFkh|ryP MXnTRW5ITVJ?
HGC-27 M{W1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rNXGlEPTB;MD61Olc5OyEQvF2= NYPxfGFRW0GQR1XS
MDA-MB-361 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzLTWM2OD1yLkW3O|YyKM7:TR?= MXfTRW5ITVJ?
KE-37 NXjjUI46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXqUWhKSzVyPUCuOVgzPiEQvF2= MXfTRW5ITVJ?
HCC70 M{GwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwNUm4Nlch|ryP Mm\lV2FPT0WU
LNCaP-Clone-FGC NHK2bFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLuZ3VSUUN3ME2wMlYyODR6IN88US=> NXzIV5F2W0GQR1XS
HAL-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPIU4JKSzVyPUCuOlIyOyEQvF2= Moq0V2FPT0WU
HT NX\pXVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELGR2pKSzVyPUCuOlMzOzlizszN NWfr[|huW0GQR1XS
MDA-MB-415 M{XRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlixTWM2OD1yLk[zOlI3KM7:TR?= MXLTRW5ITVJ?
NOS-1 NYLLeIsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTyeXFKSzVyPUCuOlM4OjNizszN M{nycnNCVkeHUh?=
DU-145 M2TZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nLdWlEPTB;MD62OFc1PSEQvF2= NEPwfHBUSU6JRWK=
OCUB-M M3nkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwN{C5OlYh|ryP MoTKV2FPT0WU
VA-ES-BJ NWizRm12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwN{OwNlUh|ryP MmHKV2FPT0WU
J-RT3-T3-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H5UWlEPTB;MD63OFQxOyEQvF2= MUHTRW5ITVJ?
MOLT-4 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[3U4JKSzVyPUCuPFA2QDJizszN MlrxV2FPT0WU
NB7 NGC0RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXPNm9KSzVyPUCuPFI1OTFizszN NGnYRWpUSU6JRWK=
L-363 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz3[|ZKSzVyPUCuPFM1PDJizszN NELreopUSU6JRWK=
NKM-1 NGrHdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED3W4NKSzVyPUCuPFYzPTNizszN NGH6ZnRUSU6JRWK=
HOP-92 NFLF[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwOEeyNlMh|ryP NIjyVVFUSU6JRWK=
OAW-42 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\NVItKSzVyPUCuPFg4OiEQvF2= NIjtNplUSU6JRWK=
HuO9 M{ezUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ez[GlEPTB;MD65Nlc2OSEQvF2= MYHTRW5ITVJ?
MFE-280 M2PBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nXRmlEPTB;MD65OlQ3PSEQvF2= MXHTRW5ITVJ?
EM-2 NHPyW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnFcpJKSzVyPUCuPVc6OzlizszN M363OHNCVkeHUh?=
NCI-H520 NVLZdJBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwOUi1PVIh|ryP NXOx[pl4W0GQR1XS
LB2241-RCC M1XnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOzXFVKSzVyPUCuPVk4OzRizszN MoLLV2FPT0WU
SK-NEP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;rU2JKSzVyPUGuNVQ1QDVizszN NXLwT2Y2W0GQR1XS
LXF-289 NVTXWolwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvJcWJSUUN3ME2xMlE4OTV4IN88US=> M3rQeXNCVkeHUh?=
EPLC-272H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrhU4tKSzVyPUGuNVczPTZizszN NUXNTlViW0GQR1XS
COLO-684 NFT0doFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMkO3NlUh|ryP NWnmXVY6W0GQR1XS
ES1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLhTWM2OD1zLkK0NFY2KM7:TR?= MX3TRW5ITVJ?
DOHH-2 NX;oOGhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwMkiyNFMh|ryP MWrTRW5ITVJ?
CTB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWz[ZJKSzVyPUGuNlg6QSEQvF2= MmTnV2FPT0WU
G-401 NUSyOpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MontTWM2OD1zLkK5O|k2KM7:TR?= NFfCdndUSU6JRWK=
LoVo Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwM{K1N|Qh|ryP NVjzeVMxW0GQR1XS
Ramos-2G6-4C10 NGGzT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqwUYZKSzVyPUGuN|M4ODFizszN NUX3SoVtW0GQR1XS
MFM-223 M2LB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfsTWM2OD1zLkO0OFYyKM7:TR?= NYfSS4JjW0GQR1XS
PA-1 NYOzTI9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwM{WyOlUh|ryP MoSwV2FPT0WU
697 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\XTWM2OD1zLkO3OlE3KM7:TR?= MVjTRW5ITVJ?
QIMR-WIL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfuN|RoUUN3ME2xMlQ6OTF4IN88US=> NVX6XlBiW0GQR1XS
HOS NX;0N|BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwNEm1OVgh|ryP NVvO[mI6W0GQR1XS
DMS-273 M2n5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[3eYlKSzVyPUGuOVE6PTlizszN NYLlcnU1W0GQR1XS
ME-180 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z5UmlEPTB;MT61Olg6OSEQvF2= NX;6e5Y4W0GQR1XS
HCC2218 NXK1So5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwNkiyNlUh|ryP MmfOV2FPT0WU
CAL-54 NGnoT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL0bWNsUUN3ME2xMlcyOjR{IN88US=> M1rDXXNCVkeHUh?=
OMC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mxTWlEPTB;MT63OFY4PyEQvF2= M2HjNXNCVkeHUh?=
COR-L105 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPuc2x7UUN3ME2xMlc6PzN5IN88US=> MnHNV2FPT0WU
BV-173 M3qxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6wTWM2OD1zLkixNFc1KM7:TR?= MnvyV2FPT0WU
RKO M1TONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwOEexNFEh|ryP MoLJV2FPT0WU
SNU-387 M4C5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT5TWM2OD1zLki4OFA3KM7:TR?= NIjVfmRUSU6JRWK=
SW1088 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmToTWM2OD1zLkm0OlA3KM7:TR?= NE[xZodUSU6JRWK=
Hs-578-T NYGxN2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwMUG0N|Mh|ryP NX;0fWdoW0GQR1XS
OC-314 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwMUWwPFYh|ryP MXrTRW5ITVJ?
RMG-I NXHTW5oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC3cZFKSzVyPUKuNVY{QThizszN MYrTRW5ITVJ?
NCI-H1395 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrDcZlKSzVyPUKuNVgxQTFizszN MmrMV2FPT0WU
GAMG NXGyW4JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJwMkO4OFUh|ryP M3nGTXNCVkeHUh?=
LB1047-RCC MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnRTWM2OD1{LkK0N|E4KM7:TR?= NH7K[IZUSU6JRWK=
MN-60 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMkm5NlMh|ryP M3rkNnNCVkeHUh?=
OAW-28 NYOyclVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrzTWM2OD1{LkK5PVUyKM7:TR?= MljtV2FPT0WU
NCI-H2228 NUX5N491T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwM{G1OVIh|ryP MYnTRW5ITVJ?
ABC-1 M1nkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJwM{OyOVMh|ryP NHr4T2ZUSU6JRWK=
LS-513 NF3Rdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwM{O0PFQh|ryP MlPOV2FPT0WU
KS-1 M2fsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwM{ixPVEh|ryP MnPQV2FPT0WU
NB69 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrxTWM2OD1{LkO4PVg{KM7:TR?= NUfPclM6W0GQR1XS
VM-CUB-1 NGPKW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S3R2lEPTB;Mj6zPVA5OyEQvF2= MW\TRW5ITVJ?
D-423MG M3qwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jOemlEPTB;Mj60NVA1PCEQvF2= NEnlZ4lUSU6JRWK=
EW-18 NWW3NlJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJwNEG5N|kh|ryP MlH4V2FPT0WU
YH-13 M2LmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3QTWM2OD1{LkS2NVU{KM7:TR?= NFOyWIxUSU6JRWK=
T-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwNEe4PFEh|ryP NIrJfWlUSU6JRWK=
ES8 NV\OelJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn4UXpKSzVyPUKuOFkzQDdizszN M1K4XnNCVkeHUh?=
ES3 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPt[mVMUUN3ME2yMlQ6PzV7IN88US=> MVTTRW5ITVJ?
RXF393 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Xy[2lEPTB;Mj62NFQ5PyEQvF2= MoGxV2FPT0WU
RPMI-8226 NIKyc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLXZ3lOUUN3ME2yMlYzQTV|IN88US=> MorTV2FPT0WU
AGS NVy0TGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwN{KxN|ch|ryP NVTGVVliW0GQR1XS
HCC1395 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[0e4tKSzVyPUKuO|UyQDdizszN MkD1V2FPT0WU
MV-4-11 M{DZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwN{WyOlYh|ryP NVLN[|ZZW0GQR1XS
A204 NF3SeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPENGtKSzVyPUKuPFM5PzJizszN M{HKUXNCVkeHUh?=
MCF7 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme0TWM2OD1{Lki2NVE4KM7:TR?= MWLTRW5ITVJ?
SNU-423 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwOEmyOFIh|ryP MXrTRW5ITVJ?
NCI-H1048 NWfSZ2szT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ey[mlEPTB;Mj65Olg3PSEQvF2= M3vTWnNCVkeHUh?=
GR-ST NWPmNpVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnqTWM2OD1|LkC0OlEyKM7:TR?= M{HRfHNCVkeHUh?=
EoL-1- NFvtT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7vTWM2OD1|LkC3NFU5KM7:TR?= M4LiVnNCVkeHUh?=
HuH-7 M1T0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonQTWM2OD1|LkC5OFY1KM7:TR?= M2rJcnNCVkeHUh?=
OS-RC-2 NYnlRmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFftPVlKSzVyPUOuNVEyQSEQvF2= M2TrZnNCVkeHUh?=
EW-3 NEnqTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj3TnBKSzVyPUOuNVk2OjlizszN M3zydHNCVkeHUh?=
NCI-H747 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwMkC2PVQh|ryP MV3TRW5ITVJ?
EW-16 M4HXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK3TWM2OD1|LkKxPFc6KM7:TR?= MV\TRW5ITVJ?
DOK MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHwTWM2OD1|LkKyPFU6KM7:TR?= NHvpPIdUSU6JRWK=
HCC2157 M{LXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXkTI1rUUN3ME2zMlM5OTd7IN88US=> Ml:2V2FPT0WU
OVCAR-3 NWTHV3FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrwXoRMUUN3ME2zMlQxPzh4IN88US=> M3r5SXNCVkeHUh?=
NCI-H1623 M4X5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwNEGyNlQh|ryP Mni2V2FPT0WU
H4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwNEW2NlYh|ryP NVT1WZRKW0GQR1XS
SW1710 NFHw[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDJOYhbUUN3ME2zMlQ3Pjd6IN88US=> NVfiOFQ6W0GQR1XS
RT-112 NH7jbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGwTWM2OD1|LkWyN|g5KM7:TR?= MUHTRW5ITVJ?
DMS-114 M{CwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTNwNkKyO|gh|ryP MlL0V2FPT0WU
AN3-CA NVXRU|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TZNmlEPTB;Mz62NlQ2PiEQvF2= NELuWGZUSU6JRWK=
KNS-62 NUfX[2hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LtdmlEPTB;Mz62N|M{QCEQvF2= NHXO[WVUSU6JRWK=
SJRH30 NITI[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTNwNkmxNlIh|ryP NEPnTXBUSU6JRWK=
G-402 M4fzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnmTHJKSzVyPUOuO|A4OTFizszN MX3TRW5ITVJ?
MHH-PREB-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe1VodPUUN3ME2zMlczODN6IN88US=> MXLTRW5ITVJ?
P30-OHK MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwOEC5O|Yh|ryP NHyzPXhUSU6JRWK=
RVH-421 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq2S|lwUUN3ME2zMlgyPzh6IN88US=> NVL2SGt3W0GQR1XS
LU-134-A M4H0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1|Lki4OFI5KM7:TR?= M1nqW3NCVkeHUh?=
ECC10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1SJFKSzVyPUOuPVM3OjJizszN M1:4fHNCVkeHUh?=
TGW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PLeGlEPTB;ND6wNlMxPSEQvF2= MWLTRW5ITVJ?
MLMA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFixe5FKSzVyPUSuNFI6PjZizszN NGqzOoxUSU6JRWK=
SCC-25 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHoTWM2OD12LkC2OVY3KM7:TR?= M{TTPXNCVkeHUh?=
TYK-nu NYeydXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf3WFBKSzVyPUSuNFk2OzRizszN M1jLXHNCVkeHUh?=
LAMA-84 NIrGSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnL[FVKSzVyPUSuNVQyQTFizszN MWDTRW5ITVJ?
Calu-3 NXXtcYs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonPTWM2OD12LkK0OFE3KM7:TR?= NXL1T4lYW0GQR1XS
NCI-H460 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofyTWM2OD12LkK2OFQ{KM7:TR?= M{\XRnNCVkeHUh?=
EGI-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfLZ|FKSzVyPUSuN|c4PzhizszN MWHTRW5ITVJ?
NCI-H292 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnvT|FuUUN3ME20MlM5OTR4IN88US=> NXnm[YZKW0GQR1XS
HCE-T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELNfW9KSzVyPUSuOFE2PzlizszN M3vHdnNCVkeHUh?=
EW-11 M2HSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7HNoczUUN3ME20MlQyQDN6IN88US=> MYPTRW5ITVJ?
ATN-1 NHXkWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC0TWM2OD12LkS0N|A1KM7:TR?= NXrlcmxSW0GQR1XS
NB5 NIG2ZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRwNUO2PVch|ryP NXPzT3VHW0GQR1XS
KLE NWn4dJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TBZ2lEPTB;ND63NFE6QCEQvF2= MY\TRW5ITVJ?
CAL-39 M1q3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrXfIw6UUN3ME20MlczOTR4IN88US=> MWjTRW5ITVJ?
TI-73 NV7Je4hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwOEC2NFkh|ryP NI\FPGlUSU6JRWK=
HO-1-N-1 M4HzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfvXFBwUUN3ME20Mlk1OiEQvF2= MnPuV2FPT0WU
786-0 NUPhbXdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTRwOUS2O|Mh|ryP MVvTRW5ITVJ?
SK-N-DZ MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rVTmlEPTB;ND65OlE1OiEQvF2= NG[yeXNUSU6JRWK=
NCI-H446 NYfRO444T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnpTWM2OD13LkKwNFA6KM7:TR?= MVTTRW5ITVJ?
ETK-1 M3zHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jPW2lEPTB;NT6yNVE3PSEQvF2= MnSyV2FPT0WU
BT-20 M{naemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vhc2lEPTB;NT6yNVM2OyEQvF2= MkDSV2FPT0WU
MEL-HO M3\VUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvuco1KSzVyPUWuN|c{OzZizszN MY\TRW5ITVJ?
CAL-27 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXqzWWRtUUN3ME21MlQ3OzN7IN88US=> NGXyfFJUSU6JRWK=
SW872 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHkXmlwUUN3ME21MlU6PDJ6IN88US=> M1nIXnNCVkeHUh?=
RPMI-2650 NWL0emo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfmUHdKSzVyPUWuOlYyQTlizszN NEDHcFJUSU6JRWK=
PFSK-1 NYXDSm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6yWo5KSzVyPUWuO|I4OzJizszN NVrGd4lXW0GQR1XS
SF295 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfCcIVMUUN3ME21MlgxPjN|IN88US=> Mn3zV2FPT0WU
Becker M13PcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTVwOE[0O|Ih|ryP M4XxfnNCVkeHUh?=
Saos-2 MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u4fmlEPTB;NT64OlU{KM7:TR?= MnXrV2FPT0WU
SK-OV-3 M2jVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGraXI1KSzVyPUWuPVk5OTZizszN NWH0cVQ3W0GQR1XS
VMRC-RCZ M331PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfqTWM2OD14LkC4O|c{KM7:TR?= MX;TRW5ITVJ?
EW-22 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTZwMUm2OFkh|ryP MWPTRW5ITVJ?
BT-474 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f2c2lEPTB;Nj6yN|Mh|ryP M3PabHNCVkeHUh?=
BFTC-909 M2LnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXuTWM2OD14LkOwN|Q2KM7:TR?= NEH1bWJUSU6JRWK=
NB12 M4DjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT0TWM2OD14LkO5NFcyKM7:TR?= M2TLXXNCVkeHUh?=
D-263MG Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonwTWM2OD14LkS1NVY6KM7:TR?= MUfTRW5ITVJ?
SNB75 M2HaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXaTWM2OD14Lk[wNVQ{KM7:TR?= MmHyV2FPT0WU
A704 M2HmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv6TWM2OD14Lk[zNFYh|ryP MYLTRW5ITVJ?
NCI-H1693 M{TZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjrXGpwUUN3ME22MlY{PjB2IN88US=> MWjTRW5ITVJ?
LN-405 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37rWWlEPTB;Nj63PVY4OiEQvF2= M1\n[HNCVkeHUh?=
CHL-1 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPpWldOUUN3ME22MlgxODd7IN88US=> MWTTRW5ITVJ?
A498 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjXN4FtUUN3ME22MlgyQTZzIN88US=> NHfZVFhUSU6JRWK=
TE-12 M3;UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrsPWNlUUN3ME22Mlg{QDF5IN88US=> NVfvNnlPW0GQR1XS
TE-6 M4XIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZwOUOwN|gh|ryP MnXDV2FPT0WU
AU565 NXywTYRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTZwOU[5OVch|ryP MV\TRW5ITVJ?
RD M2HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nyb2lEPTB;Nj65PFI5PCEQvF2= MXrTRW5ITVJ?
SW1463 NIfzNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LyU2lEPTB;Nz6xNVE3QCEQvF2= M3rlcHNCVkeHUh?=
LU-99A NFXqNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHzW4x1UUN3ME23MlE1OzJ{IN88US=> NGjXe5BUSU6JRWK=
NCI-H28 NVPPNmZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ZeHJqUUN3ME23MlI6OjRizszN MWTTRW5ITVJ?
MC-IXC Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzXeG9WUUN3ME23MlQ5PTd4IN88US=> MoTlV2FPT0WU
GP5d MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv3TWM2OD15LkS4O|Y1KM7:TR?= M13mPHNCVkeHUh?=
GB-1 M3LUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTdwNUS4NFQh|ryP Mlj1V2FPT0WU
CAL-33 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyyXI5KSzVyPUeuOlYzOzNizszN NFXEN|NUSU6JRWK=
MSTO-211H NVnOTVZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rFNWlEPTB;Nz62O|M{PiEQvF2= MmfyV2FPT0WU
TE-5 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTdwN{mzN|Qh|ryP M3XxUXNCVkeHUh?=
D-566MG MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[4TWM2OD16LkC0OFI6KM7:TR?= MVzTRW5ITVJ?
JVM-3 M4DnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfEW|FKSzVyPUiuNVUzPjhizszN MoHwV2FPT0WU
T98G M32yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrnTWM2OD16LkG4NFY4KM7:TR?= M372dHNCVkeHUh?=
HCC1954 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW4TWM2OD16LkS1NVA1KM7:TR?= NF3DS2pUSU6JRWK=
SF126 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnMbYk3UUN3ME24MlQ2QTN4IN88US=> M{P4e3NCVkeHUh?=
LB996-RCC MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn5fFRPUUN3ME24MlU{OjV5IN88US=> NF\vO|NUSU6JRWK=
SKG-IIIa MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrrT4RxUUN3ME24MlY{ODZ7IN88US=> NH3qWHFUSU6JRWK=
NCI-SNU-1 M4HIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLTS3pKSzVyPUiuOlQ3PDNizszN M{jNUnNCVkeHUh?=
LB771-HNC NWWyOVFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXQdVBKSzVyPUiuOlQ3QTZizszN NFXuN|FUSU6JRWK=
SCC-4 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LlOGlEPTB;OD62PFIyQSEQvF2= M3TVO3NCVkeHUh?=
CAMA-1 NWXRO4dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzDRmxKUUN3ME24Mlc4OTR4IN88US=> NYqwVGJLW0GQR1XS
D-502MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRThwN{i2Nlkh|ryP NUf2[nR3W0GQR1XS
ESS-1 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPOTWM2OD16Lki4O|A1KM7:TR?= MmHwV2FPT0WU
HEC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LG[mlEPTB;OD64PVg3PiEQvF2= NHrkWZdUSU6JRWK=
NB10 NUWxeWdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7aWoJsUUN3ME25MlAzOjJ2IN88US=> M4fqSnNCVkeHUh?=
8505C M3rHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv1fVBuUUN3ME25MlA1OjN{IN88US=> MVnTRW5ITVJ?
EFO-27 M{PRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPIPFdnUUN3ME25MlE3PDF{IN88US=> NEP2NG5USU6JRWK=
HN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTlwMU[2Nlgh|ryP MXHTRW5ITVJ?
DSH1 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rXdWlEPTB;OT6yNFg4KM7:TR?= NFjHc3dUSU6JRWK=
NBsusSR M2q4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDVVlVtUUN3ME25MlI4PDB{IN88US=> Mli5V2FPT0WU
LS-123 MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDxUGNCUUN3ME25MlMyPzZzIN88US=> MlHiV2FPT0WU
SHP-77 M3:xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnF[GlKSzVyPUmuN|k6OzVizszN NFz6e|ZUSU6JRWK=
ACN MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljuTWM2OD17LkWzNlc4KM7:TR?= MoDWV2FPT0WU
U251 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP6fI1HUUN3ME25MlY2PTR2IN88US=> MXzTRW5ITVJ?
A431 NIrIXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XxOmlEPTB;OT64NFI{QCEQvF2= NXvhVYxEW0GQR1XS
5637 NHfWT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nCS2lEPTB;OT64OFk5PCEQvF2= MVPTRW5ITVJ?
MDA-MB-157 NGjrW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDoTWM2OD17LkmyPFc5KM7:TR?= M1PvdXNCVkeHUh?=
A101D NIrPcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjSbWN2UUN3ME25Mlk6QTd2IN88US=> NFPCSXhUSU6JRWK=
YKG-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDoTWM2OD1zMD6yNFA3KM7:TR?= NYm2O2E{W0GQR1XS
LAN-6 M1TqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr2W5pKSzVyPUGwMlIyPjRizszN M4W1S3NCVkeHUh?=
OVCAR-5 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFyLkK0N|Mh|ryP NYjjV253W0GQR1XS
A549 M1vUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG1TWM2OD1zMD6zPVc{KM7:TR?= M3;qe3NCVkeHUh?=
no-11 M3HLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFyLkSzOVMh|ryP NITlb5FUSU6JRWK=
SF539 M4XxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f3VWlEPTB;MUCuPVA1OSEQvF2= M1LzVHNCVkeHUh?=
A388 NFfiVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFzLkO4PVch|ryP M4XkU3NCVkeHUh?=
DEL MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nSc2lEPTB;MUGuOFI1KM7:TR?= MXjTRW5ITVJ?
SW954 M1iydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPR[GxKSzVyPUGxMlQ3PjhizszN NUH2[3YzW0GQR1XS
TK10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ywOmlEPTB;MUGuOVI4OSEQvF2= M{LM[XNCVkeHUh?=
SW756 NVvHTYtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFzLkWyPVQh|ryP NWLYWIxEW0GQR1XS
PC-3 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHKTWM2OD1zMT61O|Y1KM7:TR?= Mn\BV2FPT0WU
ONS-76 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S4OmlEPTB;MUGuOlM3KM7:TR?= M13hdnNCVkeHUh?=
A427 NW\xS4ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Htd2lEPTB;MUGuO|A6OyEQvF2= NIfzT4xUSU6JRWK=
MEG-01 M37Oe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO3TWM2OD1zMT63OVA6KM7:TR?= NGnQZpNUSU6JRWK=
BB30-HNC NWHITWVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFzLke5PFIh|ryP Ml70V2FPT0WU
NCI-H1299 M2nqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnjTWM2OD1zMT64NFk{KM7:TR?= NXHGbW9VW0GQR1XS
GCT M4fTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrHPFZKSzVyPUGxMlgzOjhizszN NF;nPJhUSU6JRWK=
D-247MG MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\XbWlEPTB;MUGuPVY3OyEQvF2= MnnwV2FPT0WU
CFPAC-1 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33UWGlEPTB;MUGuPVc5OiEQvF2= NFzxV3JUSU6JRWK=
EKVX NIO1bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmwUYlRUUN3ME2xNk4xOzF|IN88US=> NXi5U|BsW0GQR1XS
CAL-51 M1K4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvVSGZvUUN3ME2xNk4xPzF4IN88US=> MmfoV2FPT0WU
BB49-HNC NVXLVXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3NXGNKSzVyPUGyMlEyPzdizszN MV;TRW5ITVJ?
RPMI-7951 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHSWFh5UUN3ME2xNk4yQDV2IN88US=> MYfTRW5ITVJ?
RH-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrDTWM2OD1zMj6yNVg1KM7:TR?= M4TtOHNCVkeHUh?=
BCPAP M{PBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvLTWM2OD1zMj60O|Q6KM7:TR?= NGjycotUSU6JRWK=
GCIY NUX3RotDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljiTWM2OD1zMj61NlA6KM7:TR?= M4j6U3NCVkeHUh?=
KNS-81-FD MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF{LkW4Olkh|ryP NYTmOIhFW0GQR1XS
KYSE-140 NE\FSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHy0O45KSzVyPUGyMlg2QTVizszN M3Wz[3NCVkeHUh?=
Ca-Ski M3fRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF{LkmwOFEh|ryP Mnr4V2FPT0WU
TGBC1TKB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3qfnpKSzVyPUGyMlkyOTVizszN MnfjV2FPT0WU
HCC1187 NH;sbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF|LkG5NVIh|ryP M4njXnNCVkeHUh?=
SJSA-1 NVr2NVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPBe2x1UUN3ME2xN{4zOzJ5IN88US=> NEC1eZRUSU6JRWK=
CTV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv3bIdKSzVyPUGzMlM1PSEQvF2= MkHtV2FPT0WU
WM-115 NVvldlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEntSo1KSzVyPUGzMlY1QDNizszN M4nu[XNCVkeHUh?=
CHP-212 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF|Lkm3N|kh|ryP MlzjV2FPT0WU
SCC-15 NHvldpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnzSJRKSzVyPUGzMlk4PzVizszN MoLPV2FPT0WU
BPH-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj1bWFKSzVyPUG0MlE3PjRizszN MUTTRW5ITVJ?
SW780 M4XQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm1fY1KSzVyPUG0MlUxOjVizszN M1\CSXNCVkeHUh?=
NCI-H2291 NHTZS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTCU5ZkUUN3ME2xOE42QDd6IN88US=> MkGyV2FPT0WU
JEG-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfZNFRUUUN3ME2xOE43OzJ4IN88US=> NWXI[WczW0GQR1XS
CAL-120 NEjDWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vpcGlEPTB;MUSuO|AzPyEQvF2= MXrTRW5ITVJ?
NCI-H23 NWC0VJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrKTWM2OD1zND63PVk4KM7:TR?= NX7ke257W0GQR1XS
MS-1 NFHCdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF2Lkm2NVEh|ryP M4TNOnNCVkeHUh?=
PC-14 M3zrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnGeIFvUUN3ME2xOE46PjV2IN88US=> M{Lnb3NCVkeHUh?=
D-283MED MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjybIFoUUN3ME2xOU4xOTFzIN88US=> M{fuenNCVkeHUh?=
OE19 NETWTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHPTWM2OD1zNT6xOVQyKM7:TR?= NEDDR3hUSU6JRWK=
CAS-1 NX3kclJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml34TWM2OD1zNT60NVg1KM7:TR?= NFz3ZVNUSU6JRWK=
NCI-H727 NWjwUI52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3voTGlEPTB;MUWuOFIzOSEQvF2= NFXrVXFUSU6JRWK=
SiHa NGHB[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHrT|R[UUN3ME2xOU44PTl2IN88US=> NVOycog4W0GQR1XS
BFTC-905 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTlfJlKSzVyPUG1Mlc3QTRizszN NVLNWGJXW0GQR1XS
MDA-MB-453 NV3VRWdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon5TWM2OD1zNj6xOlQzKM7:TR?= NETGZZdUSU6JRWK=
HuP-T3 NIjh[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF4Lk[zO|Mh|ryP M2\OZnNCVkeHUh?=
SK-LU-1 M{TYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvCTWM2OD1zNj62PVU3KM7:TR?= MlvhV2FPT0WU
Detroit562 M2myPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2zeFVSUUN3ME2xOk44OzF6IN88US=> MXHTRW5ITVJ?
HCC1569 NYnBdYl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF4LkizN|ch|ryP MXzTRW5ITVJ?
SK-MES-1 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDhTWM2OD1zNj64OFE6KM7:TR?= MWHTRW5ITVJ?
BB65-RCC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\lTWM2OD1zNz6wOFc6KM7:TR?= M3THUnNCVkeHUh?=
LOXIMVI NGi2XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF5LkC3NFch|ryP NEf6dlFUSU6JRWK=
SW1783 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MliyTWM2OD1zNz6xNlgh|ryP NFPJWYVUSU6JRWK=
NH-12 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXaOoZZUUN3ME2xO{4{OzB|IN88US=> M1XhZXNCVkeHUh?=
UACC-257 M1LIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF5LkW1NVIh|ryP M4HHbHNCVkeHUh?=
KOSC-2 NIe5S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;RemlEPTB;MUeuOlc2PyEQvF2= MV7TRW5ITVJ?
KG-1 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKzTWM2OD1zNz62PVM4KM7:TR?= MlHjV2FPT0WU
M059J Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P3ZWlEPTB;MUeuO|A{KM7:TR?= NV;rRWp5W0GQR1XS
MHH-NB-11 NWjSXJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPkW25rUUN3ME2xO{46Pjd|IN88US=> NV7QO4ZvW0GQR1XS
EW-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\yfmlEPTB;MUiuNVM5OiEQvF2= M3juR3NCVkeHUh?=
CAL-85-1 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrCSGlKSzVyPUG4MlI{PTdizszN NV7WSVduW0GQR1XS
639-V MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzBcJJ4UUN3ME2xPE4{OzV2IN88US=> NEjqbY1USU6JRWK=
C32 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETqRYRKSzVyPUG4MlQ4OjdizszN M3u4RXNCVkeHUh?=
KM-H2 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jNdWlEPTB;MUiuOVI{OiEQvF2= NUHy[ZpbW0GQR1XS
A253 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDmN2FJUUN3ME2xPE44Ojh4IN88US=> MVHTRW5ITVJ?
NCI-N87 M2e1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vxXGlEPTB;MUiuPVAxQCEQvF2= NEP6c2ZUSU6JRWK=
8-MG-BA M3PiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[5eGlKSzVyPUG5MlA3PDZizszN NIWyblZUSU6JRWK=
GI-ME-N M3zpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3yTWM2OD1zOT6xOVQ3KM7:TR?= M17We3NCVkeHUh?=
8305C NYe3OWl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF7LkKyPFYh|ryP M4m3O3NCVkeHUh?=
TE-8 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF7LkOwNlQh|ryP MXLTRW5ITVJ?
KYSE-270 NHvSN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnL[mN5UUN3ME2yNE4xOjF5IN88US=> NFG2[olUSU6JRWK=
HL-60 NIjNWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDpV5lKSzVyPUKwMlA6PDFizszN MUHTRW5ITVJ?
Mo-T MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjINFZCUUN3ME2yNE4yPjZ3IN88US=> NGjNRZNUSU6JRWK=
NCI-H1355 NVyx[JpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDOTmpEUUN3ME2yNE4{Ozd2IN88US=> NGjzPXJUSU6JRWK=
HT-1080 NHLQS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfzO|BKSzVyPUKwMlU1QTdizszN MWfTRW5ITVJ?
MIA-PaCa-2 M3nJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\KZZk{UUN3ME2yNE43QDh|IN88US=> MoXhV2FPT0WU
NCI-H441 NX\XW2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnpTWM2OD1{MD63N|c6KM7:TR?= M3j0enNCVkeHUh?=
LCLC-97TM1 M{fjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G5O2lEPTB;MkCuPFE{PCEQvF2= NET5fWtUSU6JRWK=
HT-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[0ZmlEPTB;MkGuOVY{OSEQvF2= NWnFOpoxW0GQR1XS
22RV1 M3XLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJzLkW2PFUh|ryP NW\4bWV5W0GQR1XS
LK-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDWTWM2OD1{MT61PVU{KM7:TR?= Mn\hV2FPT0WU
CW-2 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO2PXJKSzVyPUKxMlYxPjlizszN M1z6PXNCVkeHUh?=
KYSE-510 NH7zbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrld2hKSzVyPUKxMlYxQTVizszN MUDTRW5ITVJ?
CGTH-W-1 NGiwcGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXKOopKSzVyPUKxMlcyPjZizszN NXGxTppGW0GQR1XS
NCI-H661 M2nmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\NTWM2OD1{Mj6wN|Qh|ryP NUf5NmhSW0GQR1XS
KU-19-19 M2\5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGz[YVEUUN3ME2yNk4yPjl5IN88US=> M3ewWnNCVkeHUh?=
NCI-H2122 NIHkW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjLO4kzUUN3ME2yNk4zPDN{IN88US=> NYPMOHF7W0GQR1XS
NCI-H526 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ{LkO4PVUh|ryP NX\GVplKW0GQR1XS
NCI-H1650 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n4VGlEPTB;MkKuO|Y1KM7:TR?= M3zSVnNCVkeHUh?=
AM-38 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jNPGlEPTB;MkKuPFY5QSEQvF2= MYPTRW5ITVJ?
NCI-H2405 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrETWM2OD1{Mz6yOVM{KM7:TR?= MVfTRW5ITVJ?
M14 NUHCeI1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzBW2U6UUN3ME2yN{41ODh6IN88US=> NVzJfIlpW0GQR1XS
ES4 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HiWmlEPTB;MkOuOFI{OiEQvF2= MnTsV2FPT0WU
DJM-1 NXTQNXpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzTTplKSzVyPUKzMlUzOzRizszN NVPmfJVNW0GQR1XS
S-117 NH7mdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e0NmlEPTB;MkOuO|Y2OSEQvF2= NXPDbpE4W0GQR1XS
MZ2-MEL Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLBWIxKSzVyPUKzMlc4PTlizszN M3Hi[nNCVkeHUh?=
SK-MEL-2 M33pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PpO2lEPTB;MkOuPFE{OyEQvF2= MlPuV2FPT0WU
HCC1806 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfWTWM2OD1{Mz64O|A6KM7:TR?= MWjTRW5ITVJ?
NMC-G1 MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojFTWM2OD1{ND6yNlI3KM7:TR?= MV3TRW5ITVJ?
DK-MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\kWVNKSzVyPUK0MlI6PCEQvF2= M4jmS3NCVkeHUh?=
SK-N-FI NHXnTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;WTWM2OD1{ND6zN|AzKM7:TR?= M1HFUnNCVkeHUh?=
KINGS-1 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS5TWM2OD1{ND60PFc1KM7:TR?= MnvPV2FPT0WU
HCC2998 NFfoepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ2LkS4PFUh|ryP MmfmV2FPT0WU
ALL-PO NX62RphKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ2Lk[xPUDPxE1? NWTyV3N[W0GQR1XS
MPP-89 NXHaN3NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInlTWlKSzVyPUK1MlA1PThizszN Mkn5V2FPT0WU
NCI-H2342 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ3LkG5OVMh|ryP Mm\6V2FPT0WU
TE-1 NHruXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ3LkO1OlMh|ryP NVrmVGp{W0GQR1XS
RH-18 NF;ORmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ3LkW5NVgh|ryP MnnmV2FPT0WU
HT-1376 M2nGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HIPWlEPTB;MkWuOlQ3PSEQvF2= MlruV2FPT0WU
U-2-OS M322bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2PW5KSzVyPUK1MlY5QDhizszN MYDTRW5ITVJ?
BT-549 M1LMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrFdINKSzVyPUK1MlkxOTFizszN NGXoOG9USU6JRWK=
NCI-H1755 NY\RVHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjuO3g5UUN3ME2yOU46QTR3IN88US=> NYP4PHM1W0GQR1XS
EW-13 M4HnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ4LkCyO|Qh|ryP MYDTRW5ITVJ?
NB13 NGfyZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H0SGlEPTB;Mk[uNFk1QSEQvF2= NG\hS5pUSU6JRWK=
NUGC-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\pNmlEPTB;Mk[uNlExOyEQvF2= NUX0cmdLW0GQR1XS
GMS-10 M1PORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqyR2c{UUN3ME2yOk4zOzV|IN88US=> MlvSV2FPT0WU
CHP-134 NGH6VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m2VWlEPTB;Mk[uN|g3PyEQvF2= NEnzcWZUSU6JRWK=
SW962 NV\Ue3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETzO5FKSzVyPUK2MlUxOjFizszN M{TBXnNCVkeHUh?=
SNU-449 Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MornTWM2OD1{Nz6wPFA{KM7:TR?= M16xRnNCVkeHUh?=
HuP-T4 M3XZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDVU|ZiUUN3ME2yO{4xQDd7IN88US=> NXnlSGFvW0GQR1XS
SW948 NYTST4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KxfmlEPTB;MkeuNVM1PCEQvF2= MX3TRW5ITVJ?
NCI-H226 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\KTWM2OD1{Nz60OVc5KM7:TR?= M1\4[XNCVkeHUh?=
SK-PN-DW NFW4UVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JWoRkUUN3ME2yO{43ODF{IN88US=> M4XOXHNCVkeHUh?=
GI-1 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDwTWM2OD1{Nz63NlEh|ryP NGm3THhUSU6JRWK=
CAL-12T MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P2R2lEPTB;MkiuNVEyOiEQvF2= M1yzcnNCVkeHUh?=
YAPC NULDZodiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP6TWM2OD1{OD6yOVY1KM7:TR?= M1HpW3NCVkeHUh?=
SNU-C2B NWfodZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LKN2lEPTB;MkiuNlk3PCEQvF2= MYDTRW5ITVJ?
RCC10RGB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ6LkW0NVch|ryP Moj6V2FPT0WU
ES7 M37xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3jTWM2OD1{OT6xOFY2KM7:TR?= MmfxV2FPT0WU
PANC-03-27 M1fIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP1fW5KSzVyPUK5MlQ1PCEQvF2= NIjC[VhUSU6JRWK=
ES6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDkWmNKSzVyPUK5MlgyPTdizszN MlfMV2FPT0WU
HT-1197 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\wPWlEPTB;M{CuNFU6QCEQvF2= M4S0S3NCVkeHUh?=
ZR-75-30 NG\rV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjHNmlwUUN3ME2zNE4zOzh|IN88US=> NEHrWnpUSU6JRWK=
DB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DFbmlEPTB;M{CuOFk1OiEQvF2= NFTBfWVUSU6JRWK=
OCI-AML2 NGjEPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TTSWlEPTB;M{GuNFY6KM7:TR?= M{LpZnNCVkeHUh?=
NCI-H2170 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[xcWhJUUN3ME2zNU45PTF4IN88US=> NFXHVnpUSU6JRWK=
IST-MES1 M2K3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HBSGlEPTB;M{KuNlg6PyEQvF2= M2XyU3NCVkeHUh?=
769-P NHv4TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm2fHlyUUN3ME2zNk4{PjRzIN88US=> NEHLTGVUSU6JRWK=
COR-L23 NIjQS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuwXFFKSzVyPUOyMlkxPzNizszN MmrWV2FPT0WU
SW626 NEjaWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN|LkG3O|Yh|ryP M3qydnNCVkeHUh?=
LU-139 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;HdHdKSzVyPUOzMlY3ODVizszN Mnm4V2FPT0WU
HT-144 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGwd4dKSzVyPUOzMlg3OyEQvF2= NYLWVllpW0GQR1XS
CaR-1 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjIUI9KSzVyPUOzMlk5OjJizszN NVq4dWlvW0GQR1XS
OE33 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DZOmlEPTB;M{SuNlg2PSEQvF2= M3;BNHNCVkeHUh?=
COLO-800 NGXGTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLQTWM2OD1|ND6zOlQ4KM7:TR?= MXXTRW5ITVJ?
NB14 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TJNmlEPTB;M{SuOFY5PCEQvF2= MVTTRW5ITVJ?
KURAMOCHI MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN4LkGxPVgh|ryP Mmj3V2FPT0WU
SW48 NIPxOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnOTWM2OD1|Nj6yOFc1KM7:TR?= M1\vOnNCVkeHUh?=
Daoy M4P2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrzV4tqUUN3ME2zOk43PTN6IN88US=> MX7TRW5ITVJ?
TGBC24TKB M3fWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hh[GlEPTB;M{[uOlch|ryP M3HMO3NCVkeHUh?=
DU-4475 NHn5WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jUOGlEPTB;M{[uPVA{OyEQvF2= Ml3rV2FPT0WU
SW1417 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XnbWlEPTB;M{iuNFU2OiEQvF2= MkLyV2FPT0WU
EFO-21 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[zTWM2OD1|OD65N|Q6KM7:TR?= MV\TRW5ITVJ?
MG-63 M3jIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXjTWM2OD1|OT6zOFI1KM7:TR?= NWfoe5l2W0GQR1XS
LC-2-ad MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjIN3RKSzVyPUO5MlU2OTJizszN M4rLeXNCVkeHUh?=
NOMO-1 NG[xfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonJTWM2OD1|OT64Nlc1KM7:TR?= MlLPV2FPT0WU
COLO-741 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\y[mlEPTB;NECuNVMxPCEQvF2= NXLqO2dNW0GQR1XS
BxPC-3 NU\abmJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7kRXBKSzVyPUSwMlU3QDZizszN NXXKboRsW0GQR1XS
HSC-2 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;PfmlEPTB;NECuPVEyOyEQvF2= M2nNfHNCVkeHUh?=
UMC-11 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzDTWM2OD12MT6yOlMh|ryP NFu3eVRUSU6JRWK=
HCC1937 M{exeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjzc5FKSzVyPUSyMlc5PDNizszN Mn:yV2FPT0WU
Calu-6 NW[0SWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHQfYNnUUN3ME20N{4zOzh{IN88US=> NFruPGhUSU6JRWK=
NCI-H1573 NFT3Z2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDkTmxNUUN3ME20N{4{PDd5IN88US=> NVr1eXV3W0GQR1XS
SK-N-AS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fLdGlEPTB;NEOuOlAyQSEQvF2= MoCyV2FPT0WU
PSN1 NXq4T3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX70fnpqUUN3ME20OU4zPTR6IN88US=> M4XpbXNCVkeHUh?=
TE-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;5WoRKSzVyPUS1MlQ5PDJizszN M3;zXHNCVkeHUh?=
NCI-H1155 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXobmQ3UUN3ME20OU45QTZ5IN88US=> M1ThSXNCVkeHUh?=
KM12 NXvhR5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[zdGxKSzVyPUS1MlkxPzZizszN MVTTRW5ITVJ?
RO82-W-1 NW[0U3FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfE[FBWUUN3ME20Ok46QDJ{IN88US=> NHvVS5lUSU6JRWK=
SW1573 NEHpOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjyTWM2OD12Nz6zO|M3KM7:TR?= NIq5PXVUSU6JRWK=
CAKI-1 NF2ybpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTR6LkK4OFUh|ryP MVLTRW5ITVJ?
U-118-MG NXOyPZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTxWXBKSzVyPUS4MlM4ODJizszN MlLvV2FPT0WU
KYSE-520 M1vpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTR6LkSwNVYh|ryP NIf5cohUSU6JRWK=
HT55 NEO5d2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzXUHRKSzVyPUS5MlE1PzRizszN MoDsV2FPT0WU
ChaGo-K-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR7LkS3PVMh|ryP NGP4WGdUSU6JRWK=
IA-LM NUfqU5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDqRppXUUN3ME21OE43OzJ{IN88US=> NF\QRYdUSU6JRWK=
UACC-62 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLxTZBZUUN3ME21OU4yODR4IN88US=> MVLTRW5ITVJ?
MKN7 NXfv[nZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvBfpJKSzVyPUW2MlAzQDVizszN MXrTRW5ITVJ?
HPAF-II NXyw[mE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHxdnVKSzVyPUW2MlQxPzNizszN NHrpclNUSU6JRWK=
NTERA-S-cl-D1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzrTWhIUUN3ME21O{44PzhizszN M3H0OXNCVkeHUh?=
FTC-133 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXJVYdDUUN3ME21PE4xQTZ7IN88US=> MlHEV2FPT0WU
MHH-ES-1 MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfETWM2OD13OD60PFE1KM7:TR?= Ml:0V2FPT0WU
JVM-2 M3HqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[0V3V[UUN3ME21PE46PTB4IN88US=> MlqzV2FPT0WU
TCCSUP NELrfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi4NZoxUUN3ME21PU42Ojd7IN88US=> M1nucHNCVkeHUh?=
COLO-824 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33IR2lEPTB;NkCuNFcyQSEQvF2= MVvTRW5ITVJ?
647-V MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTZyLkGzOFch|ryP MX;TRW5ITVJ?
HD-MY-Z NXXKNJltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTZyLkWyPVQh|ryP Mli5V2FPT0WU
LS-411N MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTZzLkO5NFMh|ryP Mn;2V2FPT0WU
NCI-H596 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTZ{Lke0PVYh|ryP M{f6cnNCVkeHUh?=
C-33-A NWDlfopnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvjTWM2OD14ND6wPVU4KM7:TR?= MWfTRW5ITVJ?
BHY MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml20TWM2OD14ND6xNlQ2KM7:TR?= NFLROYRUSU6JRWK=
KGN NYX0TopQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzGW3Z5UUN3ME22OE42PTF2IN88US=> NYrP[FhLW0GQR1XS
NCI-H1092 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLlTWM2OD14NT6wNFk2KM7:TR?= M4XwTHNCVkeHUh?=
MZ1-PC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXQTWM2OD14NT61OlQ6KM7:TR?= NIHHZmhUSU6JRWK=
LB831-BLC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZ3Lki0PFEh|ryP MWDTRW5ITVJ?
SW620 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTZ4LkKwN|kh|ryP NXHTUWFCW0GQR1XS
HuO-3N1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj3TWM2OD14OD6zNlM5KM7:TR?= MUfTRW5ITVJ?
SK-HEP-1 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OzU2lEPTB;NkmuPVQ5PiEQvF2= MUHTRW5ITVJ?
LCLC-103H MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[wTWM2OD15MD62O|A2KM7:TR?= MmXxV2FPT0WU
KYSE-70 NHvSN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvhTWM2OD15MD63PFM2KM7:TR?= MWTTRW5ITVJ?
Mewo MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rCdmlEPTB;N{GuOVA2KM7:TR?= MofvV2FPT0WU
COLO-668 NITucFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTdzLki0OVEh|ryP MonSV2FPT0WU
NCI-H522 NF\XNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfHN41{UUN3ME23Nk4{PDF|IN88US=> NUjVUGF1W0GQR1XS
NCI-H1437 M3GzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fXc2lEPTB;N{SuOFA1QCEQvF2= MnjnV2FPT0WU
U-266 NWDlSVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7HVXA4UUN3ME23OU41PTF4IN88US=> NVrrOIdbW0GQR1XS
MC116 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\0VmlEPTB;N{WuOVcxQCEQvF2= M4q1dXNCVkeHUh?=
PANC-10-05 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTd5LkSyOFMh|ryP NXjxSnlmW0GQR1XS
KYSE-180 NGrYZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT6OIdKSzVyPUe3MlU1PTRizszN NXHLOpJlW0GQR1XS
JAR NV\6d2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzMd5F5UUN3ME23PU4xPTR4IN88US=> MWfTRW5ITVJ?
CAL-62 M4iwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRThyLkC5OUDPxE1? MnToV2FPT0WU
A3-KAW MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmxe|JKSzVyPUiwMlIyPTRizszN NHPyVlZUSU6JRWK=
PANC-08-13 M2DFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\YVZZZUUN3ME24NU4yPzZ6IN88US=> M33XRnNCVkeHUh?=
HSC-3 NHHlbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLOTWM2OD16Mz6zNFcyKM7:TR?= MXrTRW5ITVJ?
HTC-C3 M{\ZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Bc2lEPTB;OEOuOFcxOiEQvF2= MUjTRW5ITVJ?
KY821 NHrZXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnmcVVUUUN3ME24OE4xQDl{IN88US=> NGXsPIlUSU6JRWK=
DoTc2-4510 NGTw[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnHRVNIUUN3ME24OE4zOTh3IN88US=> MmjGV2FPT0WU
NCI-H1581 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDpTWM2OD16NT60OlQyKM7:TR?= NFW4N49USU6JRWK=
KARPAS-299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H4O2lEPTB;OE[uNVk4PyEQvF2= M3;iPXNCVkeHUh?=
IST-MEL1 NYLE[o1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M375cmlEPTB;OE[uPFg4OiEQvF2= NInrVXdUSU6JRWK=
KP-N-YS NVrjPIIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTh7LkmwNlgh|ryP MV3TRW5ITVJ?
KYSE-410 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qNGlEPTB;OUGuOFA1OiEQvF2= MVfTRW5ITVJ?
TE-10 NH7qPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\tR5I2UUN3ME25NU42PjFzIN88US=> MXjTRW5ITVJ?
SK-MEL-1 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV75V3AzUUN3ME25Nk46OTB4IN88US=> M4TucnNCVkeHUh?=
COLO-792 NF;BXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfBTWM2OD17NT6yOVY1KM7:TR?= M1TrTnNCVkeHUh?=
SCH NUX3eIwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rQd2lEPTB;OU[uN|g4PyEQvF2= NFr5[nJUSU6JRWK=
NCI-H1792 NF\HWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjyTHdKSzVyPUm2Mlg6QTJizszN MXfTRW5ITVJ?
NCI-H2029 M3L2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT6TWM2OD17Nj65OVY3KM7:TR?= NYPoc5RiW0GQR1XS
SW684 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPLb4lsUUN3ME25PE43PjV2IN88US=> MnnKV2FPT0WU
NCI-H209 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj4TWM2OD1zMECuNVIyKM7:TR?= MYrTRW5ITVJ?
HLE MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnibI5JUUN3ME2xNFUvOjh{IN88US=> M2S0SXNCVkeHUh?=
GOTO MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn6d3VlUUN3ME2xNFcvPzd5IN88US=> MXPTRW5ITVJ?
NCI-H1793 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfiTWM2OD1zMEmuNlgh|ryP MoW5V2FPT0WU
D-392MG M{jhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPaUXkxUUN3ME2xNVcvOzl6IN88US=> NGDPdWpUSU6JRWK=
SW1990 NX3kcXdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlTWM2OD1zMkCuPVUyKM7:TR?= NHPwOGRUSU6JRWK=
ML-2 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DRSmlEPTB;MUKxMlY4PiEQvF2= MmHIV2FPT0WU
NCI-H2452 M4\rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HpcmlEPTB;MUKyMlIyKM7:TR?= M4PJNHNCVkeHUh?=
SK-MEL-30 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETJNWdKSzVyPUGyN{4zPDRizszN Mnz3V2FPT0WU
SN12C MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf6flhKSzVyPUGyOE4yPzZizszN NXTUfWdHW0GQR1XS
NCI-H1770 M3\Sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF{NT61NVQh|ryP M2HQe3NCVkeHUh?=
SF268 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy2d41KSzVyPUGyOk4yPThizszN NFrjPVdUSU6JRWK=
BALL-1 NXL2e3lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvkTWM2OD1zMk[uNlMh|ryP MlXGV2FPT0WU
COLO-679 NHzCVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF{Nj63OVMh|ryP NXHkbnBEW0GQR1XS
A2780 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqwTWM2OD1zMkiuPVg5KM7:TR?= MlO1V2FPT0WU
NCI-H1651 M3vRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCzTWM2OD1zM{GuNlQ{KM7:TR?= MnLyV2FPT0WU
NCI-H2087 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DvRWlEPTB;MUOxMlQ5OyEQvF2= NIHqPYNUSU6JRWK=
U-87-MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTSTWM2OD1zM{OuOlA1KM7:TR?= MnXDV2FPT0WU
LB2518-MEL NF3ERnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi0TWM2OD1zM{WuPVk{KM7:TR?= M4jpOnNCVkeHUh?=
HCT-116 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH2T5FKSzVyPUGzO{4zOTdizszN NEK5fY1USU6JRWK=
Ca9-22 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX73c5J7UUN3ME2xN|kvQDN|IN88US=> Mn\qV2FPT0WU
COR-L88 NGfLZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF2Mj6xOEDPxE1? NF;NeoZUSU6JRWK=
CP50-MEL-B MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrO[XZKSzVyPUG0OE42ODFizszN MVPTRW5ITVJ?
OVCAR-8 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Gxd2lEPTB;MUS1MlY{PiEQvF2= MVrTRW5ITVJ?
SK-MEL-3 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSyd|I2UUN3ME2xOFcvQDd6IN88US=> MVfTRW5ITVJ?
GT3TKB NYj3S|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnUOpB5UUN3ME2xOFkvQTJ6IN88US=> MUHTRW5ITVJ?
KYSE-450 M4GyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\IRnRjUUN3ME2xOVEvPTN7IN88US=> MkHHV2FPT0WU
CAPAN-1 M{S3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInoVVZKSzVyPUG1N{4xPjRizszN NYKyTnE6W0GQR1XS
BEN MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;5RY5KSzVyPUG1N{46OjhizszN MWXTRW5ITVJ?
NCI-H1304 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF3ND62PVQh|ryP NYr1V5A1W0GQR1XS
KU812 NHS1RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT6fpZKSzVyPUG1PE43PzRizszN NIfFO2tUSU6JRWK=
Capan-2 NXfRfphIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;1PGlEPTB;MU[wMlU2OyEQvF2= NVXFUYF5W0GQR1XS
A673 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF4MT63NFUh|ryP M4LFe3NCVkeHUh?=
SAS NFf1VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXJV|h4UUN3ME2xOlIvPjd6IN88US=> NGr6dWtUSU6JRWK=
NY MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF4NT6zNVQh|ryP NYX3b4RHW0GQR1XS
HCE-4 MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXvZ|ZKSzVyPUG2Ok45PDVizszN NVLDOYJRW0GQR1XS
MDA-MB-231 M{fBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF5Nz61NFMh|ryP NFzjPYpUSU6JRWK=
no-10 NW\PNoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\KTWM2OD1zN{iuNVM1KM7:TR?= MmTJV2FPT0WU
MZ7-mel NUHsTXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\tS2lEPTB;MUe4MlQ3PyEQvF2= NIjCPYZUSU6JRWK=
NCI-H82 M{m3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO5S5RKSzVyPUG4NE4yPjVizszN Ml;lV2FPT0WU
CAL-72 M2K2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\OUIJKSzVyPUG4OU4xPTRizszN NGG2WWhUSU6JRWK=
NCI-SNU-5 NVG3SZlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF6Nj64OEDPxE1? Ml\UV2FPT0WU
OVCAR-4 NVmxNoVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF6OD6zN|Mh|ryP MkPjV2FPT0WU
SCC-9 M4fRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvZOYs6UUN3ME2xPVEh|ryP M{LlVHNCVkeHUh?=
KYSE-150 M2TuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH36dmhKSzVyPUG5NU45QDhizszN M1LSUXNCVkeHUh?=
HT-29 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjnXlJKSzVyPUKwNU4zOTJizszN MlW1V2FPT0WU
COLO-678 NFjpcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELYOWRKSzVyPUKwNU41PSEQvF2= NFfCc4dUSU6JRWK=
NCI-H650 M1zLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jERmlEPTB;MkCyMlExOyEQvF2= Mlf2V2FPT0WU
HuCCT1 M1WyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n4R2lEPTB;MkC0MlIxQCEQvF2= MnfxV2FPT0WU
SW1116 NFvHNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJyNz6wO|ch|ryP NHv3bHVUSU6JRWK=
DBTRG-05MG Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLjUVlKSzVyPUKwO{46ODlizszN M1;pTnNCVkeHUh?=
SW982 NWPvbIh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJyNz65OFgh|ryP M4PMVXNCVkeHUh?=
RCM-1 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJzND63OlIh|ryP NVXMdVFSW0GQR1XS
COLO-320-HSR NGDBU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXXPHVKSzVyPUKxOk4yOjVizszN NW\FOFY4W0GQR1XS
KNS-42 NXHZNo1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJzNj61O|Qh|ryP NV\Sc|dMW0GQR1XS
C2BBe1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ|MT65NFUh|ryP NX\TV4pGW0GQR1XS
CCRF-CEM Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\w[GlEPTB;MkSzMlc6PSEQvF2= NIrOcGZUSU6JRWK=
SH-4 NXfhdXF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\NOYRKSzVyPUK0Ok4xQSEQvF2= MXfTRW5ITVJ?
LS-1034 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nqN2lEPTB;MkS2MlI3PiEQvF2= MV;TRW5ITVJ?
NCI-H2347 M{X2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XacGlEPTB;MkS3MlcyOyEQvF2= NYDEd2ZXW0GQR1XS
RPMI-8866 NWrKbnN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULRO4RrUUN3ME2yOFkvOjdizszN MXrTRW5ITVJ?
GAK MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHyTWM2OD1{NUOuNFAzKM7:TR?= M1z2[XNCVkeHUh?=
NB6 NUDsc2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ5MD6xJO69VQ>? M1[0bXNCVkeHUh?=
COLO-680N MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnXXIFKSzVyPUK3Nk42OjdizszN NXnFPWIyW0GQR1XS
RERF-LC-MS NWPi[GZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3RTWM2OD1{N{[uNFA4KM7:TR?= M3;ybnNCVkeHUh?=
TGBC11TKB M2nRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPh[G9KSzVyPUK3PE4yPzhizszN NH3NZYJUSU6JRWK=
C8166 M4jWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXvWYJoUUN3ME2yO|gvPTB4IN88US=> M2HMUXNCVkeHUh?=
HDLM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ7ND60NFkh|ryP NH7CbnpUSU6JRWK=
IGR-1 M131O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ7NT62OVkh|ryP M3G2e3NCVkeHUh?=
FADU MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ7Nz61NUDPxE1? NIezfmJUSU6JRWK=
L-428 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ7Nz62NVYh|ryP MkHsV2FPT0WU
LU-65 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DJXWlEPTB;M{C0MlMzKM7:TR?= MoP3V2FPT0WU
HEL NVS5eWE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTSVJpKSzVyPUOwPU46QDNizszN NXKzd|FwW0GQR1XS
NCI-H810 NEX4b5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfiUYhKSzVyPUOxNE42PyEQvF2= M3jUN3NCVkeHUh?=
C3A NV\uSXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq3Z2lKSzVyPUOxNU45ODJizszN M3vZW3NCVkeHUh?=
NCI-H630 M2nlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPzdXNKSzVyPUOzNk4zQTRizszN NUnsV5lqW0GQR1XS
KP-N-YN MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDvTWM2OD1|NEGuNVI{KM7:TR?= NH3NZ5lUSU6JRWK=
MOLT-13 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:zdnRNUUN3ME2zOFIvOzJ4IN88US=> MUTTRW5ITVJ?
NCI-H1993 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO3c|BwUUN3ME2zOFIvOzZ3IN88US=> NF\RNG5USU6JRWK=
BE-13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PqNmlEPTB;M{S0MlE3PyEQvF2= MorWV2FPT0WU
IST-SL1 M3[3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX0VoVKSzVyPUO0O{41ODFizszN M4T5d3NCVkeHUh?=
TE-9 NFvI[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojCTWM2OD1|NkOuOVg6KM7:TR?= MXPTRW5ITVJ?
LU-135 NILjW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K0U2lEPTB;M{[3MlA{PSEQvF2= MmnpV2FPT0WU
T84 M{O5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN5ND63NVIh|ryP MVPTRW5ITVJ?
K-562 NVH0clFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr5TWM2OD1|OEOuN|Yh|ryP M{\WZ3NCVkeHUh?=
SBC-5 NY\MepE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTN6Nj65PFUh|ryP NETueJBUSU6JRWK=
NB17 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTxTWM2OD1|OUKuOVk3KM7:TR?= MX3TRW5ITVJ?
NCI-H2052 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle4TWM2OD1|OUiuOFczKM7:TR?= NXHnV3ZSW0GQR1XS
HCC38 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSwZ|FKSzVyPUSwNU42QTNizszN NEXMbWdUSU6JRWK=
NCI-H69 NUDucGlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TmPGlEPTB;NESxMlA5OyEQvF2= Mm\XV2FPT0WU

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01802320 Active not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01802320 Active not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01783171 Completed Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 15 2013 Phase 1
NCT01776008 Terminated Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 : AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) : Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products4

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • Capivasertib (AZD5363)

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID